Insight into the regulatory mechanism of β-arrestin2 and its emerging role in diseases

Br J Pharmacol. 2024 Sep;181(17):3019-3038. doi: 10.1111/bph.16488. Epub 2024 Jul 3.

Abstract

β-arrestin2, a member of the arrestin family, mediates the desensitization and internalization of most G protein-coupled receptors (GPCRs) and functions as a scaffold protein in signalling pathways. Previous studies have demonstrated that β-arrestin2 expression is dysregulated in malignant tumours, fibrotic diseases, cardiovascular diseases and metabolic diseases, suggesting its pathological roles. Transcription and post-transcriptional modifications can affect the expression of β-arrestin2. Furthermore, post-translational modifications, such as phosphorylation, ubiquitination, SUMOylation and S-nitrosylation affect the cellular localization of β-arrestin2 and its interaction with downstream signalling molecules, which further regulate the activity of β-arrestin2. This review summarizes the structure and function of β-arrestin2 and reveals the mechanisms involved in the regulation of β-arrestin2 at multiple levels. Additionally, recent studies on the role of β-arrestin2 in some major diseases and its therapeutic prospects have been discussed to provide a reference for the development of drugs targeting β-arrestin2.

Keywords: G protein‐coupled receptors; post‐translational modification; signalling transduction; β‐arrestin2.

Publication types

  • Review

MeSH terms

  • Animals
  • Cardiovascular Diseases / metabolism
  • Humans
  • Neoplasms / drug therapy
  • Neoplasms / metabolism
  • Neoplasms / pathology
  • Protein Processing, Post-Translational
  • Signal Transduction
  • beta-Arrestin 2* / metabolism

Substances

  • beta-Arrestin 2